SubHero Banner

Hemlibra® (emicizumab-kxwh) – Expanded indication

October 4, 2018 - Genentech announced the FDA approval of Hemlibra (emicizumab-kxwh), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.

Download PDF